Loosening Medicaid restrictions on hep C drugs could improve patient access, study finds
05 Apr 2024
While state Medicaid programs have increasingly loosened coverage restrictions on hepatitis C drugs in recent years, a team of researchers at Harvard University recently published a study finding that a further easing of restrictions could improve uptake.
In a paper published in JAMA on Friday, the researchers examined 39 Medicaid programs between 2015 and 2020, 32 of which eased restrictions on direct-acting antivirals to treat hepatitis C. Medicaid programs had initially set restrictions on coverage of the antivirals because they were expensive, but over the years coverage has expanded as prices have come down and in response to litigation and advocacy.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.